| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges.
|
J Clin Psychiatry
|
2008
|
2.86
|
|
2
|
Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine.
|
Int J Neuropsychopharmacol
|
2005
|
1.50
|
|
3
|
Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia.
|
J Clin Psychiatry
|
2007
|
1.21
|
|
4
|
Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients.
|
Schizophr Res
|
2007
|
1.09
|
|
5
|
Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort.
|
J Psychiatr Res
|
2008
|
1.05
|
|
6
|
Diagnostic stability 18 months after treatment initiation for first-episode psychosis.
|
J Clin Psychiatry
|
2005
|
1.00
|
|
7
|
The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.
|
CNS Drugs
|
2009
|
0.99
|
|
8
|
Rationale and content of psychenet: the Hamburg Network for Mental Health.
|
Eur Arch Psychiatry Clin Neurosci
|
2012
|
0.99
|
|
9
|
A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders.
|
J Child Adolesc Psychopharmacol
|
2007
|
0.97
|
|
10
|
Under what circumstances do patients with schizophrenia jump to conclusions? A liberal acceptance account.
|
Br J Clin Psychol
|
2007
|
0.95
|
|
11
|
Integrated care in patients with schizophrenia: results of trials published between 2011 and 2013 focusing on effectiveness and efficiency.
|
Curr Opin Psychiatry
|
2013
|
0.93
|
|
12
|
Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis.
|
Schizophr Bull
|
2011
|
0.93
|
|
13
|
Schneiderian first rank symptoms predict poor outcome within first episode manic psychosis.
|
J Affect Disord
|
2004
|
0.92
|
|
14
|
Prevalence and predictors of suicide attempt in an incidence cohort of 661 young people with first-episode psychosis.
|
Aust N Z J Psychiatry
|
2009
|
0.91
|
|
15
|
Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial).
|
J Clin Psychiatry
|
2012
|
0.90
|
|
16
|
Early Psychosis Prevention and Intervention Centre long-term follow-up study of first-episode psychosis: methodology and baseline characteristics.
|
Early Interv Psychiatry
|
2007
|
0.88
|
|
17
|
Pretreatment and outcome correlates of past sexual and physical trauma in 118 bipolar I disorder patients with a first episode of psychotic mania.
|
Bipolar Disord
|
2010
|
0.87
|
|
18
|
Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study.
|
Psychopharmacology (Berl)
|
2007
|
0.86
|
|
19
|
Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics.
|
J Child Adolesc Psychopharmacol
|
2005
|
0.85
|
|
20
|
Prediction of functional outcome 18 months after a first psychotic episode: a proton magnetic resonance spectroscopy study.
|
Arch Gen Psychiatry
|
2006
|
0.84
|
|
21
|
Pretreatment and outcome correlates of sexual and physical trauma in an epidemiological cohort of first-episode psychosis patients.
|
Schizophr Bull
|
2009
|
0.84
|
|
22
|
Validation of a Clinical Global Impression Scale for Aggression (CGI-A) in a sample of 558 psychiatric patients.
|
Schizophr Res
|
2008
|
0.84
|
|
23
|
Predictors of service disengagement in first-admitted adolescents with psychosis.
|
J Am Acad Child Adolesc Psychiatry
|
2006
|
0.83
|
|
24
|
Rate and predictors of service disengagement in an epidemiological first-episode psychosis cohort.
|
Schizophr Res
|
2010
|
0.83
|
|
25
|
Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism.
|
Prog Neuropsychopharmacol Biol Psychiatry
|
2004
|
0.83
|
|
26
|
Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management.
|
CNS Drugs
|
2015
|
0.82
|
|
27
|
The impact of subjective well-being under neuroleptic treatment on compliance and remission.
|
Dialogues Clin Neurosci
|
2006
|
0.82
|
|
28
|
Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.
|
J Psychiatr Res
|
2007
|
0.81
|
|
29
|
Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors.
|
Expert Opin Pharmacother
|
2008
|
0.81
|
|
30
|
Socioeconomic status and beliefs about depression, schizophrenia and eating disorders.
|
Soc Psychiatry Psychiatr Epidemiol
|
2012
|
0.81
|
|
31
|
Manifestation of multiple sclerosis with paranoid-hallucinatory psychosis.
|
J Neurol
|
2006
|
0.81
|
|
32
|
Familial psychopathology in the First Episode Psychosis Outcome Study.
|
Aust N Z J Psychiatry
|
2008
|
0.80
|
|
33
|
Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye.
|
J Control Release
|
2010
|
0.80
|
|
34
|
Reduced auditory evoked gamma band response and cognitive processing deficits in first episode schizophrenia.
|
World J Biol Psychiatry
|
2015
|
0.79
|
|
35
|
Symptomatic and functional outcome 12 months after a first episode of psychotic mania: barriers to recovery in a catchment area sample.
|
Bipolar Disord
|
2006
|
0.79
|
|
36
|
Sudden death among young people with first-episode psychosis: An 8-10 year follow-up study.
|
Psychiatry Res
|
2010
|
0.79
|
|
37
|
Estimated prevalence of mental disorders and the desire for social distance--results from population surveys in two large German cities.
|
Psychiatry Res
|
2013
|
0.78
|
|
38
|
Cannabis use disorder and age at onset of psychosis--a study in first-episode patients.
|
Schizophr Res
|
2011
|
0.78
|
|
39
|
Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.
|
Eur Psychiatry
|
2006
|
0.78
|
|
40
|
Drug safety and efficacy evaluation of sertindole for schizophrenia.
|
Expert Opin Drug Saf
|
2012
|
0.78
|
|
41
|
Pre-morbid and outcome correlates of first episode mania with psychosis: is a distinction between schizoaffective and bipolar I disorder valid in the early phase of psychotic disorders?
|
J Affect Disord
|
2010
|
0.78
|
|
42
|
Patterns and correlates of expressed emotion, perceived criticism, and rearing style in first admitted early-onset schizophrenia spectrum disorders.
|
J Nerv Ment Dis
|
2014
|
0.77
|
|
43
|
Early specific cognitive-behavioural psychotherapy in subjects at high risk for bipolar disorders: study protocol for a randomised controlled trial.
|
Trials
|
2014
|
0.77
|
|
44
|
Brief Psychiatric Rating Scale - Excited Component (BPRS-EC) and neuropsychological dysfunction predict aggression, suicidality, and involuntary treatment in first-episode psychosis.
|
Schizophr Res
|
2012
|
0.77
|
|
45
|
[Sexual problems in patients with schizophrenia].
|
Psychiatr Prax
|
2009
|
0.77
|
|
46
|
[Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
|
Psychiatr Prax
|
2004
|
0.76
|
|
47
|
Gender differences in first episode psychotic mania.
|
BMC Psychiatry
|
2013
|
0.76
|
|
48
|
Differentiating schizoaffective and bipolar I disorder in first-episode psychotic mania.
|
Schizophr Res
|
2012
|
0.75
|
|
49
|
Should we listen and talk more to our patients?
|
World Psychiatry
|
2013
|
0.75
|
|
50
|
'Stoned': Schneiderian first-rank symptoms as a manifestation of bilateral obstructive urolithiasis.
|
Br J Psychiatry
|
2010
|
0.75
|
|
51
|
Comorbidity of schizophrenia and galactosemia: effective clozapine treatment with weight gain.
|
Int Clin Psychopharmacol
|
2003
|
0.75
|
|
52
|
Predictors of substance use reduction in an epidemiological first-episode psychosis cohort.
|
Early Interv Psychiatry
|
2013
|
0.75
|
|
53
|
Effectiveness of integrated care including therapeutic assertive community treatment in severe schizophrenia spectrum and bipolar I disorders: the 24-month follow-up ACCESS II study.
|
J Clin Psychiatry
|
2014
|
0.75
|
|
54
|
Subjective well-being in schizophrenia: a randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER).
|
Eur Neuropsychopharmacol
|
2013
|
0.75
|